THE LONDON ENDOCRINE CENTRE LIMITEDActive
Key figures
Like most small UK companies, THE LONDON ENDOCRINE CENTRE LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.
Balance sheet structure
Dividends
from the accountsDividends paid in the financial year: £30,000 (10% of the profit for the year).
Filed accounts2022–2024
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Profit for the year | 370,330 | 299,379 | — |
| Cash at bank and in hand | 623,658 | 776,937 | 889,625 |
| Total assets | 1,924,843 | 2,187,954 | — |
| Total liabilities | 209,537 | 203,032 | — |
| Net assets / total equity | 1,714,019 | 1,983,398 | 2,109,673 |
| Average number of employees | 3 | 5 | 5 |
| Dividends paid | — | 30,000 | — |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
Principal activity
Accounts 2024The principal activity of the company continued to be that of medical consultation concerning endocrinological diseases and issues.
As described in the company's latest filed accounts.
Summary: THE LONDON ENDOCRINE CENTRE LIMITED
Company
THE LONDON ENDOCRINE CENTRE LIMITED is a private limited company registered with Companies House under company number 07461728. It was incorporated on 7 Dec 2010. Its status is active. The registered office is in Oxford (OX2). Its nature of business (SIC 2007) is general medical practice activities (86210).
Accounts
The latest accounts in the database are for 2024 (period ending 31 Dec 2024); the company files small company accounts (filleted). Net assets were £2,109,673, up 6.4% on the previous year. Cash at bank and in hand was £889,625. The company had an average of 5 employees. Figures are available for 3 financial years (2022–2024).
Control and charges
One person with significant control is registered.
Filing deadlines
The next accounts are due by 31 Dec 2026. The next confirmation statement is due by 21 Dec 2026.